脑供血不足伴纤维蛋白原增高应用降纤酶治疗的临床效果  

Clinical Efficacy of Defibrinogenase in the Treatment of Brain Ischemiawith High Plasmafibrinogen

作　　者：张珊珊 余芾成[1] ZHANG Shanshan;YU Feicheng(Xiaogan Central Hospital,Xiaogan 432000,China)

机构地区：[1]湖北省孝感市中心医院

出　　处：《中国医学创新》2019年第29期29-32,共4页Medical Innovation of China

摘　　要：目的:探讨伴纤维蛋白原增高脑供血不足患者应用降纤酶治疗的临床效果。方法:选取2015年2月-2018年2月本院收治的102例脑供血不足伴纤维蛋白原增高患者,通过抛硬币法随机分组原则分为研究组(n=51)和常规组(n=51)。常规组给予常规治疗,研究组应用降纤酶治疗。分析比较两组的临床效果。结果:研究组总有效率为98.04%,高于常规组的84.31%(P<0.05)。两组治疗前凝血四项各指标水平比较,差异均无统计学意义(P>0.05);研究组治疗后凝血四项各指标均有积极改善,且均优于常规组(P<0.05)。两组治疗前血液流变学指标比较,差异均无统计学意义(P>0.05);研究组治疗后血液流变学指标均有积极改善,且均优于常规组(P<0.05)。结论:对脑供血不足伴纤维蛋白原增高患者采用降纤酶治疗方案,治疗效果优异,值得推广。Objective: To study the clinical effect of Defibrinogenasein the treatment of brain ischemiawith high plasmafibrinogen. Method: A total of 102 patients with brain ischemiawith high plasmafibrinogenfrom February 2015 to February 2018 were randomly divided into the study group(n=51) and the routine group(n=51) by the principle of random grouping by coin flipping. The routine group was given conventional treatment, the study group was given Defibrinogenase. The clinical effects of two groups were compared. Result: The total effective rate of the study group was 98.04%, higher than 84.31% of the routine group(P<0.05). There were no differences in the levels of blood coagulation system text of two groups before treatment(P>0.05). The four coagulation indicators in the study group improved positively after treatment, and were better than those in the routine group(P<0.05). There were no significant differences in hemorheological indexes between two groups before treatment(P>0.05). The hemorheological indexes of the study group improved positively after treatment, and were better than those of the routine group(P<0.05). Conclusion: Defibrinogenase treatment regimen is used in patients brain ischemia with high plasmafibrinogen, the therapeutic effect is excellent and it is worthy of promotion.

关 键 词：降纤酶 纤维蛋白原增高 脑供血不足 

分 类 号：R[医药卫生]